Clinical Trial Update: Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa [Phase 3]

View source ↗

Summary

Phase 3 study of KW-6002 (istradefylline) as add-on therapy to levodopa for Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• KW-6002 (istradefylline) (istradefylline)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED